Health China

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors
1. 2009 Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clinical Cancer Research Jun 23
2. 2009 A novel analytic approach to the prediction of respiratory diaphragm motion based on external torso volume change Phys. Med. Biol. 54(13):4113-30
3. 2009 Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Molecular Cancer Therapeutics 8(6): 1589-95
4. 2009 Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis Cell Cycle 8(13): 2093-100
5. 2009 Molecular Targets for Tumor Radiosensitization. Chemical Reviews Apr 2 Epub
6. 2009 In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clinical Cancer Research 15(2): 607-12
7. 2009 Introduction. Seminar Introduction. Seminar in Radiation Oncology 19(3):141
8. 2009 Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters. Radiation research 171: 236-244
9. 2009 In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase1/2 kinase Clinical Cancer Research Apr 14 2009 Epub
10. 2009 Tofilon, PJ: Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro Molecular Cancer Research 7: 489-97
11. 2008 Clinical Cancer Research Clinical Cancer Research 14(13): 4241-9
12. 2008 Principles of radiation oncology Cancer Management: a multidisciplinary approach. 11th Edition
13. 2008 Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis and Review 27(3): 415-34
14. 2008 Advancement of antiangiogenic and vascular disrupting agents combined with radiation Cancer Treat Res 139:153-71
15. 2008 Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clinical Cancer Research 14(17): 5410-5
16. 2008 Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations JCO 26(24): 3987-94
17. 2008 Safety and immunological response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clincal Cancer Research 14(16): 5284-91
18. 2008 Radiation-induced gene translation profiles reveal tumor type and cancer-specific components Cancer Research 68(10):3819-26
19. 2008 Post-collection, pre-measuremnt variablesaffecting VEGF levels in urine biospecimens. Cell Mol Med. 12(1):343-50
20. 2008 Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects . Cancer Immunol Immunother 57(8): 1173-83
21. 2008 Quantitative method to study the network formation of endothelial cells in response to tumor angiogenic factor. Clin Can Res 14(3): 931-8
22. 2008 Advances in 4D medical imaging and 4D radiation therapy Technol Cancer Res Treat. 7(1):67-82
23. 2008 Non-patient related variables affecting levels of vascular endothelial growth factor in urine biospecimens. J Cell Mol Med 12(4): 1250-55
24. 2008 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma Journal of Clinical Oncology
25. 2008 Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments . Journal of Applied Clinical Medical Physics 9(4), 2781
26. 2008 Neuropsychological testing and biomarkers in the management of brain metastases Radiation Oncology 3:26
27. 2007 Evaluation of novel agents as radiosensitizers from laboratory to clinic. ASCO Educational Book 705-708
28. 2007 Inhibition of HSP90: a multitarget approach to radiosensitization. Clinical Cancer Research 13: 4326-30
29. 2007 Inhibition of histone deacetylation: a strategy for tumor radiosensitization Journal of Clinical Oncology 25: 4051-
30. 2007 The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology Cancer 111(3): 173-84
31. 2007 Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 110(1): 441-9
32. 2007 Topology of the heterogeneous nature of the extracellular matrix on stochastic modeling of tumor-induced angiogenesis. Microvascular Research Nov 22
33. 2007 Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in quality of life measured by epic score Int J Radiat Oncol Biol Phys 70(1): 90-5
34. 2007 Synergistic antitumor activity of immune strategies combined with radiation. Frontiers in Bioscience 12:4900-10
35. 2007 Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study Radiation Oncology 2:19
36. 2006 An endogenous inhibitor of endothelial cell growth from transitional cell carcinoma clipped β2-glycoprotein-I. Annals of Surgical Oncology 13(9): 1241-51
37. 2006 Anti-angiogenic and anti-tumor effects of Bevacizumab in inflammatory and locally advanced breast cancer patients Journal of Clinical Oncology 24: 769-777
38. 2006 Intra and inter-therapist reproducibility of daily isocenter verification using prostatic fiducial markers. Radiat Oncol 1(1): 2
39. 2006 Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T MRI scanner . Journal of Urology 175(1): 113-20
40. 2006 Discovering clinical biomarkers of ionizing radiation exposure with serum proeomic analysis Cancer Research 66(3): 1844-50
41. 2006 Radiation-induced changes in gene expression involve recruitment of existing mRNAs to and away from polysomes. Cancer Research 66(2): 1052-61
42. 2006 A dosimetric analysis of dose escalation using two intensity modulated radiation therapy techniques in locally advanced, unresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 65(1): 274-83
43. 2006 Intrarectal Amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study. Int J Radiat Oncol Biol Phys 65(4): 1008-13,
44. 2006 Radiation modultes the peptide repertoire of MHC class I molecules and induces successful anti-tumor immunotherapy. J Exp Med 203(5): 1259-71
45. 2006 Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells. Mol Cancer Ther. 5(6): 1504-10
46. 2006 A pilot trial of a carcinoembryonic antigen/TRICOM-based vaccine and radiation to liver metastasis in patients with carcinoembryonic antigen-positive solid tumors Clin Colorectal Cancer 6(1): 72-5
47. 2006 Enhancement of anti-tumor activity against mesothelin expressing tumor xenografts using the combination of tumor directed radiation and the immunotoxin SS1P. Clinical Cancer Research 12(16): 4983-8
48. 2006 Clinical relevance of maspin expression in bladder cancer World Journal of Urology 24(3): 338-44
49. 2006 Early Observed Transient Prostate-Specific Antigen Elevations On a Pilot Study of External Beam Radiation Therapy and Fractionated MRI Guided High Dose Rate Brachytherapy Boost Radiation Oncology August 16;1:28
50. 2006 Inhibition of Hsp90 compromises the DNA damage response to radiation. . Cancer Research 66(18):9211-20
51. 2006 Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism Journal of the National cancer Institute 98(22): 1634-46
52. 2006 Why Radiation Oncology Radiat Oncol 1(1): 1
53. 2006 Combining radiotherapy and angiogenesis inhibitors: clinical trial design International Journal of Radiation Oncology, Biology and Physics 64(1): 15-25
54. 2005 An interventional MRI technique for the molecular characterization of intra-prostatic dynamic contrast enhancement Molecular Imaging 4(1): 63-66
55. 2005 Inverse Treatment Planning Based on MRI for HDR Prostate Brachytherapy. International Journal of Radiation Oncology Biology and Physics 61(4): 1267-75
56. 2005 Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. International Journal of Cancer 114(3): 380-6
57. 2005 Combining angiogenesis inhibitors with radiation. 7th ICDTF. Mehta, M., Paliwal, B., and Bentzen, S. Medical Physics Publishing. Pages 16-30
58. 2005 Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clinical Cancer Research 11(12): 4571-9
59. 2005 Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. Proceeding of the National Academy of Sciences 102(23): 8287-92
60. 2005 Volumetric voxel image registration: development for multi-modality image fusion International Journal of Radiation Oncology Biology and Physics 63(1): 261-73
61. 2005 Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clinical Cancer Research 11(9): 3353-3362
62. 2005 Early ipsilateral breast tumor recurrences after breast conservation affects survival: an analysis of the NCI randomized trial International Journal of Radiation Oncology Biology and Physics 62(3): 785-9
63. 2005 Quantitative method to study the network formation of endothelial cells in response to tumor angiogenic factor. IEE Proceedings Systems Biology 152(2): 61-66
64. 2005 Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. International Journal of Radiation Oncology Biology and Physics 62(5): 1316-21
65. 2005 Implications for tumor control during protection of normal tissues with antioxidants Journal of Clinical Oncology 23(24): 5455-7
66. 2005 Orthotopic growth of human glioma cells increases their susceptibility to radiation-induced modifications in gene expression. Cancer Research 65(22): 10389-93
67. 2005 ErbB3 expression predicts tumor cell radiosensitization induced by HSP90 inhibition Cancer Research 65(15): 6967-75
68. 2005 Inhibition of NF-kB and target genes during combined therapy with proteasome inhibitor Bortezomib and re-irradiation in patients with recurrent head and neck squamous cell carcinoma. International Journal of Radiation Oncology Biology and Physics 63(5): 1400-1412
69. 2005 The requirement of multimodality therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors Clinical Cancer Research 11(12): 4533-44
70. 2004 Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy International Journal of Radiation Oncology Biology and Physics 58(5): 1536-39
71. 2004 Enhanced cell killing induced by the combination of radiation and the histone deacetylase inhibitor MS-275. Cancer Research 64: 316-21
72. 2004 The combination of angiogenesis inhibitors and radiotherapy for the treatment of primary tumors. In: Pharmacokinetics and pharmacodymanics of anti-cancer drugs. Eds: William Figg and Howard McLeod. Humana Press Totowa, NJ. Pages 431-438
73. 2004 The present and future of molecularly targeted therapy, Chapter in “Clinical Oncology Editors. Elsevier Churchill and Livingstone. Pages 623-638
74. 2004 MRI-Guided HDR Prostate Brachytherapy in a Standard 1.5T Scanner International Journal of Radiation Oncology Biology and Physics 59(5): 1414-23
75. 2004 Combining radiation and molecular targeting in cancer therapy Cancer Biology and Therapy, 3(3): 247-50
76. 2004 Murine in vivo imaging and its role in preclinical modeling of novel agents Expert review of Anticancer Therapy, 4(5): 857-864,
77. 2004 In vivo tumor imaging utilizing a near-infrared labeled Endostatin molecule International Journal of Radiation Oncology Biology and Physics 58(2): 536-541
78. 2004 Three-color labeling method for flow cytometric analysis of cytogenetic damge in rodent and human blood. Environmental Molecular Mutagenesis 44(5): 427-35
79. 2004 Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor DMAG (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin). Clinical Cancer Research 10(23): 8077-84
80. 2004 Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation Clinical Cancer Research 10(18): 6066-71
81. 2004 Microarray analysis in clinical oncology: pre-clinical optimization using needle core biopsies from xenograft tumors BMC Cancer 4(1): 20
82. 2004 Microarray analysis of gliosarcoma tissue. Check Sample Clinical Chemistry 44(5): 51-63
83. 2004 System for prostate brachytherapy and biopsy in a standard 1.5T MRI scanner Magnetic Resonance Medicine 52(3): 683-7
84. 2004 External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Research 62(12): 4328-4337
85. 2004 Evaluation of chelating agents as anti-angiogenic therapy through copper chelation Bioorganic Medicinal Chemistry 12(19): 5133-40
86. 2004 In vivo tumor imaging in mice with near infrared labeled Endostatin. Molecular Cancer Therapeutics 3(4): 481-488
87. 2004 Effect of angiogenesis inhibitors on cyclophosphamide induced bladder inflammation in mice Angiogenesis 7(1): 69-73
88. 2004 Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gH2AX foci Molecular Cancer Therapeutics 3(4): 409-416
89. 2004 Predictive significance of urinary vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) levels and trends in patients with cancer . Journal of Clinical Oncology 22(3): 499-506
90. 2003 Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Research 63: 7377-7383
91. 2003 Vascular Endothelial Growth Factor effect upon angiogenesis and hypercoagulopathy in glioblastoma multiforme and other conditions. Check Sample. Clinical Chemistry 43
92. 2003 Irradiation of tumor cells upregulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy Journal of Immunology 170: 6338-47
93. 2003 Evaluation of copper chelation agents as anti-angiogenic therapy. Bioorganic and Medicinal Chemistry 11(19): 4287-93
94. 2003 Angiogenic tumor markers, anti-angiogenic agents and radiation therapy. Expert Review of Anti-cancer therapy 3(3): 357-
95. 2003 Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results Seminars In Oncology 30(6): 62-66
96. 2003 Enhanced cell killing induced by the combination of radiation and the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multi-target approach to radiosensitization. Clinical Cancer Research 9:3749-3755
97. 2003 Development of investigational radiation modifiers. Journal of the National Cancer Institute 95(9): 646-651
98. 2003 Radiation abscopal anti-tumor effect is mediated through p53. Cancer Research April 15; 63: 1990-1993
99. 2003 A mathematical approach to the antiangiogenic hypothesis. Bulletin of Mathematical Biology 65: 407-424
100. 2002 Tumor hypoxia: chicken, egg or a piece of the farm? Journal of Clinical Oncology, Feb 1: 20(3): 610-615
101. 2002 Angiogenesis inhibitors and radiotherapy of primary tumors. Expert Opinion on Biological Therapy. 2(5); 477-481
102. 2002 A portrait of an editorial board member Cell Cycle. 1(5); 296-297
103. 2002 Combination therapy with anti-angiogenic agents and radiotherapy European Journal of Cancer, 13 (13 Suppl.),
104. 2001 In vivo gene expression profile analysis of early diabetic retinopathy. Investigational Ophthalmology and Visual Sciences, Nov 1; 42(12): 3047-3057
105. 2001 Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Research 61(5): 2207-11
106. 2001 What does radiotherapy do to the endothelial cells? Science 293: 114-116
107. 2001 Low dose ionizing irradiation for the inhibition of posterior capsule opacification. International Journal of Radiation Oncology and Physics 49(3): 817-25
108. 1995 Diversity of T-cell receptor V-alpha, V-beta and CDR3 gene utilization in the human response to myelin basic protein. Neurology 45: 1919-1922
109. 1995 TCR alpha and beta CDR3 expression by myelin basic protein specific human T cell clones Acad. Sci 756: 317-318
110. 1994 HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2MBP, in multiple sclerosis. J. Immunology 153: 4834-4844

Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.